NCT07253129 Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)
| NCT ID | NCT07253129 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Condition | Peripheral T Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 88 participants |
| Start Date | 2025-12-31 |
| Primary Completion | 2029-05-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the autologous hematopoietic stem cell transplantation group (Auto-HSCT). It aims to evaluate the efficacy and safety of Auto-HSCT and Allo-HSCT in the treatment of peripheral T-cell lymphoma that has achieved partial response (PR) after first-line therapy. During the screening/baseline period, informed consent will be obtained, and inclusion/exclusion criteria will be verified. Group assignment (Allo-HSCT vs. Auto-HSCT) will be determined taking into account the availability of a matched donor and the patient's preference. The study plans to enroll 44 patients in the allogeneic hematopoietic stem cell transplantation group, while all concurrent patients undergoing autologous stem cell transplantation will be included in the other group for inverse probability weighting analysis. Data on demographics and medical history will be collected, and assessments including vital signs, physical examination, PET-CT, bone marrow aspiration smear, flow cytometry, and bone marrow pathology will be performed.
Eligibility Criteria
Inclusion Criteria: 1. Age \& Sex: Males or females aged 18 to 70 years (inclusive). 2. ECOG performance status score of 0 to 1, with no deterioration within the last two weeks. 3. Expected survival period greater than 12 weeks. 4. Patients must have a histopathological confirmation of PTCL according to the 2016 revised WHO classification of lymphoid neoplasms (Swerdlow SH et al. 2016). Eligible histological subtypes are limited to the following: * Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) * Anaplastic large cell lymphoma, ALK-negative (ALK-ALCL) * Follicular helper T-cell lymphoma or PTCL with TFH phenotype (FTCL or PTCL-TFH) Patients undergoing allogeneic hematopoietic stem cell transplantation must have a suitable stem cell donor: (i) Related donors must be at least 5/10 matched for HLA-A, -B, -C, -DQB1, and -DRB1. (ii) Unrelated donors must be at least 8/10 matched for HLA-A, -B, -C, -DQB1, and -DRB1. 5. Patients must have achieved a partial response (PR) as pe